BAT5906 vs MW02

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

BAT5906

Developed by Bio-Thera Solutions

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody
Partial signal

NCT05439629 · Phase 3 · completed

The study randomized 488 participants to BAT5906 or active treatment with Lucentis and masked participants, care providers, and investigators. Its primary outcomes were clinical measures of visual acuity, but the registry does not report whether the comparison was favorable or statistically significant, so the evidence remains limited pending results.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

MW02

Developed by Mabwell Bioscience and partners

Phase 2/3 in Age-Related Macular Degenerationmonoclonal antibody
Partial signal

NCT05297292 · Phase 2/3 · status unknown

The seamless Phase 2/3 trial randomized 476 patients with wet AMD to MW02 or ranibizumab under double masking. The sponsor reports that the 1.5 mg dose was non-inferior to ranibizumab on best-corrected visual acuity at week 52; the registry has no posted results.

Caveat: this result is taken from a company announcement, not from the trial registry or a peer-reviewed publication. Treat it as the sponsor's own statement.

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

BAT5906: no structured comparison results are available for Age-Related Macular Degeneration.

MW02: no structured comparison results are available for Age-Related Macular Degeneration.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT5906's landscape · MW02's landscape